Metagenomi(US:MGX) Prnewswireยท2024-11-04 10:45Group 1 - The lawsuit is on behalf of shareholders who purchased Metagenomi, Inc. (NASDAQ: MGX) shares during the initial public offering (IPO) period from February 9 to 13, 2024 [1] - Metagenomi's IPO involved selling 6.25 million shares at a price of $15 per share, and the company claimed a significant partnership with Moderna, which was a key aspect of its business model [2] - The collaboration with Moderna was terminated on May 1, 2024, leading to a decline in Metagenomi's stock price from $7.04 to $6.17 per share within a day [2] Group 2 - Shareholders are encouraged to register for the class action lawsuit by November 25, 2024, to potentially become lead plaintiffs and receive updates on the case [3] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4]